{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:54:15Z","timestamp":1794563655394,"version":"4.9.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1038\/s41584-020-0372-x","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T13:02:46Z","timestamp":1581080566000},"page":"155-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1236,"title":["Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology"],"prefix":"10.1038","volume":"16","author":[{"given":"Eva","family":"Schrezenmeier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"372_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 73, 492\u2013509 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis, A. et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 78, 736\u2013745 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","volume":"77","author":"BA Pons-Estel","year":"2018","unstructured":"Pons-Estel, B. A. et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann. Rheum. Dis. 77, 1549\u20131557 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/rheumatology\/kex286","volume":"57","author":"C Gordon","year":"2018","unstructured":"Gordon, C. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology 57, e1\u2013e45 (2018).","journal-title":"Rheumatology"},{"key":"372_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou, M. G. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann. Rheum. Dis. 78, 1296\u20131304 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/BOR.0000000000000096","volume":"26","author":"P Brito-Zeron","year":"2014","unstructured":"Brito-Zeron, P., Ramos-Casals, M. & EULAR-SS task force group. Advances in the understanding and treatment of systemic complications in Sjogren\u2019s syndrome. Curr. Opin. Rheumatol. 26, 520\u2013527 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"372_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.rdc.2016.03.010","volume":"42","author":"FB Vivino","year":"2016","unstructured":"Vivino, F. B. et al. New treatment guidelines for Sjogren\u2019s disease. Rheum. Dis. Clin. North. Am. 42, 531\u2013551 (2016).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"372_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza, G. et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69, 20\u201328 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/rheumatology\/keq350","volume":"50","author":"M Ostensen","year":"2011","unstructured":"Ostensen, M. et al. Pregnancy and reproduction in autoimmune rheumatic diseases. Rheumatology 50, 657\u2013664 (2011).","journal-title":"Rheumatology"},{"key":"372_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3899\/jrheum.120572","volume":"40","author":"PS Akhavan","year":"2013","unstructured":"Akhavan, P. S. et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J. Rheumatol. 40, 831\u2013841 (2013).","journal-title":"J. Rheumatol."},{"key":"372_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1191\/0961203305lu2039oa","volume":"14","author":"CC Mok","year":"2005","unstructured":"Mok, C. C., Mak, A. & Ma, K. M. Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106\u2013112 (2005).","journal-title":"Lupus"},{"key":"372_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","volume":"13","author":"M Petri","year":"2011","unstructured":"Petri, M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr. Rheumatol. Rep. 13, 77\u201380 (2011).","journal-title":"Curr. Rheumatol. Rep."},{"key":"372_CR13","doi-asserted-by":"publisher","first-page":"385","DOI":"10.7326\/M17-1430","volume":"168","author":"SR Kingsbury","year":"2018","unstructured":"Kingsbury, S. R. et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann. Intern. Med. 168, 385\u2013395 (2018).","journal-title":"Ann. Intern. Med."},{"key":"372_CR14","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.23471","volume":"70","author":"W Lee","year":"2018","unstructured":"Lee, W. et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 70, 1320\u20131325 (2018).","journal-title":"Arthritis Care Res."},{"key":"372_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault, C. et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 77, 98\u2013103 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR16","doi-asserted-by":"publisher","first-page":"R109","DOI":"10.1186\/ar2764","volume":"11","author":"G Ruiz-Irastorza","year":"2009","unstructured":"Ruiz-Irastorza, G. et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res. Ther. 11, R109 (2009).","journal-title":"Arthritis Res. Ther."},{"key":"372_CR17","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nrmicro3138","volume":"11","author":"EL Flannery","year":"2013","unstructured":"Flannery, E. L., Chatterjee, A. K. & Winzeler, E. A. Antimalarial drug discovery \u2013 approaches and progress towards new medicines. Nat. Rev. Microbiol. 11, 849\u2013862 (2013).","journal-title":"Nat. Rev. Microbiol."},{"key":"372_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/415686a","volume":"415","author":"RG Ridley","year":"2002","unstructured":"Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686\u2013693 (2002).","journal-title":"Nature"},{"key":"372_CR19","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.drudis.2014.06.018","volume":"19","author":"M Minie","year":"2014","unstructured":"Minie, M. et al. CANDO and the infinite drug discovery frontier. Drug Discov. Today 19, 1353\u20131363 (2014).","journal-title":"Drug Discov. Today"},{"key":"372_CR20","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nature12051","volume":"496","author":"CJ Paddon","year":"2013","unstructured":"Paddon, C. J. et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 496, 528\u2013532 (2013).","journal-title":"Nature"},{"key":"372_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4269\/ajtmh.2007.77.198","volume":"77","author":"V Hale","year":"2007","unstructured":"Hale, V. et al. Microbially derived artemisinin: a biotechnology solution to the global problem of access to affordable antimalarial drugs. Am. J. Trop. Med. Hyg. 77, 198\u2013202 (2007).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"372_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.cbpa.2011.05.017","volume":"15","author":"W Mitchell","year":"2011","unstructured":"Mitchell, W. Natural products from synthetic biology. Curr. Opin. Chem. Biol. 15, 505\u2013515 (2011).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"372_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.tig.2014.12.005","volume":"31","author":"DJ Conway","year":"2015","unstructured":"Conway, D. J. Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet. 31, 97\u2013107 (2015).","journal-title":"Trends Genet."},{"key":"372_CR24","first-page":"529","volume":"5","author":"K Karunamoorthi","year":"2014","unstructured":"Karunamoorthi, K. Malaria vaccine: a future hope to curtail the global malaria burden. Int. J. Prev. Med. 5, 529\u2013538 (2014).","journal-title":"Int. J. Prev. Med."},{"key":"372_CR25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/1871526510909030304","volume":"9","author":"TA de Beer","year":"2009","unstructured":"de Beer, T. A. et al. Antimalarial drug discovery: in silico structural biology and rational drug design. Infect. Disord. Drug Targets 9, 304\u2013318 (2009).","journal-title":"Infect. Disord. Drug Targets"},{"key":"372_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.molbiopara.2006.10.011","volume":"151","author":"M Vedadi","year":"2007","unstructured":"Vedadi, M. et al. Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organisms. Mol. Biochem. Parasitol. 151, 100\u2013110 (2007).","journal-title":"Mol. Biochem. Parasitol."},{"key":"372_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.tmaid.2012.12.003","volume":"11","author":"CO Buckee","year":"2013","unstructured":"Buckee, C. O. et al. Mobile phones and malaria: modeling human and parasite travel. Travel. Med. Infect. Dis. 11, 15\u201322 (2013).","journal-title":"Travel. Med. Infect. Dis."},{"key":"372_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001413","volume":"10","author":"SI Hay","year":"2013","unstructured":"Hay, S. I. et al. Big data opportunities for global infectious disease surveillance. PLoS Med. 10, e1001413 (2013).","journal-title":"PLoS Med."},{"key":"372_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","volume":"16","author":"C Ponticelli","year":"2017","unstructured":"Ponticelli, C. & Moroni, G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert. Opin. Drug Saf. 16, 411\u2013419 (2017).","journal-title":"Expert. Opin. Drug Saf."},{"key":"372_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-017-1543-z","volume":"18","author":"SQ Wang","year":"2017","unstructured":"Wang, S. Q. et al. Is hydroxychloroquine effective in treating primary Sjogren\u2019s syndrome: a systematic review and meta-analysis. BMC Musculoskelet. Disord. 18, 186 (2017).","journal-title":"BMC Musculoskelet. Disord."},{"key":"372_CR31","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2174\/1568026614666140808125728","volume":"14","author":"S Manohar","year":"2014","unstructured":"Manohar, S., Tripathi, M. & Rawat, D. S. 4-aminoquinoline based molecular hybrids as antimalarials: an overview. Curr. Top. Med. Chem. 14, 1706\u20131733 (2014).","journal-title":"Curr. Top. Med. Chem."},{"key":"372_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford, K. D. et al. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology 23, 231\u2013269 (2015).","journal-title":"Inflammopharmacology"},{"key":"372_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/jm00138a014","volume":"24","author":"DT Witiak","year":"1981","unstructured":"Witiak, D. T. et al. Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues. J. Med. Chem. 24, 712\u2013717 (1981).","journal-title":"J. Med. Chem."},{"key":"372_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/tera.1420520305","volume":"52","author":"CN Tagoe","year":"1995","unstructured":"Tagoe, C. N. & Ofori-Adjei, D. Effects of chloroquine and its enantiomers on the development of rat embryos in vitro. Teratology 52, 137\u2013142 (1995).","journal-title":"Teratology"},{"key":"372_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1365-2125.1995.tb05768.x","volume":"40","author":"J Ducharme","year":"1995","unstructured":"Ducharme, J. et al. Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. Br. J. Clin. Pharmacol. 40, 127\u2013133 (1995).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"372_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/chir.530060420","volume":"6","author":"SE Tett","year":"1994","unstructured":"Tett, S. E. et al. Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality 6, 355\u2013359 (1994).","journal-title":"Chirality"},{"key":"372_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","volume":"27","author":"SE Tett","year":"1989","unstructured":"Tett, S. E. et al. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br. J. Clin. Pharmacol. 27, 771\u2013779 (1989).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"372_CR38","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","volume":"5","author":"DE Furst","year":"1996","unstructured":"Furst, D. E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 5, S11\u2013S15 (1996).","journal-title":"Lupus"},{"key":"372_CR39","first-page":"142","volume":"24","author":"DJ Cutler","year":"1988","unstructured":"Cutler, D. J., MacIntyre, A. C. & Tett, S. E. Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials. Agents Actions Suppl. 24, 142\u2013157 (1988).","journal-title":"Agents Actions Suppl."},{"key":"372_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","volume":"75","author":"EW McChesney","year":"1983","unstructured":"McChesney, E. W. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am. J. Med. 75, 11\u201318 (1983).","journal-title":"Am. J. Med."},{"key":"372_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0033-3182(93)71870-8","volume":"34","author":"DA Fishbain","year":"1993","unstructured":"Fishbain, D. A. et al. Do some chronic pain patients with atypical facial pain overvalue and obsess about their pain? Psychosomatics 34, 355\u2013359 (1993).","journal-title":"Psychosomatics"},{"key":"372_CR42","first-page":"145","volume":"44","author":"S Tett","year":"1993","unstructured":"Tett, S. et al. Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine. Agents Actions Suppl. 44, 145\u2013190 (1993).","journal-title":"Agents Actions Suppl."},{"key":"372_CR43","first-page":"1874","volume":"20","author":"SE Tett","year":"1993","unstructured":"Tett, S. E., Day, R. O. & Cutler, D. J. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis \u2013 a cross sectional study. J. Rheumatol. 20, 1874\u20131879 (1993).","journal-title":"J. Rheumatol."},{"key":"372_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.117.245639","volume":"365","author":"KP Collins","year":"2018","unstructured":"Collins, K. P., Jackson, K. M. & Gustafson, D. L. Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation. J. Pharmacol. Exp. Ther. 365, 447\u2013459 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"372_CR45","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1177\/0961203393002001051","volume":"2","author":"RI Rynes","year":"1993","unstructured":"Rynes, R. I. & Bernstein, H. N. Ophthalmologic safety profile of antimalarial drugs. Lupus 2, S17\u2013S19 (1993).","journal-title":"Lupus"},{"key":"372_CR46","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/art.10307","volume":"46","author":"T Munster","year":"2002","unstructured":"Munster, T. et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 46, 1460\u20131469 (2002).","journal-title":"Arthritis Rheum."},{"key":"372_CR47","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/00007691-200312000-00005","volume":"25","author":"SJ Carmichael","year":"2003","unstructured":"Carmichael, S. J., Charles, B. & Tett, S. E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 25, 671\u2013681 (2003).","journal-title":"Ther. Drug Monit."},{"key":"372_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2125.1994.tb04316.x","volume":"38","author":"V Spaldin","year":"1994","unstructured":"Spaldin, V. et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 38, 15\u201322 (1994).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"372_CR49","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1124\/dmd.31.6.748","volume":"31","author":"D Projean","year":"2003","unstructured":"Projean, D. et al. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab. Dispos. 31, 748\u2013754 (2003).","journal-title":"Drug Metab. Dispos."},{"key":"372_CR50","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/14622416.8.2.187","volume":"8","author":"JP Gil","year":"2007","unstructured":"Gil, J. P. & Gil Berglund, E. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 8, 187\u2013198 (2007).","journal-title":"Pharmacogenomics"},{"key":"372_CR51","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1080\/0049825031000121608","volume":"33","author":"D Projean","year":"2003","unstructured":"Projean, D. et al. Identification of CYP3A4 and CYP2C8 as the major cytochrome P450 s responsible for morphine N-demethylation in human liver microsomes. Xenobiotica 33, 841\u2013854 (2003).","journal-title":"Xenobiotica"},{"key":"372_CR52","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF02976712","volume":"26","author":"KA Kim","year":"2003","unstructured":"Kim, K. A. et al. Cytochrome P450 2C8 and CYP3A4\/5 are involved in chloroquine metabolism in human liver microsomes. Arch. Pharm. Res. 26, 631\u2013637 (2003).","journal-title":"Arch. Pharm. Res."},{"key":"372_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","volume":"59","author":"XQ Li","year":"2003","unstructured":"Li, X. Q. et al. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol. 59, 429\u2013442 (2003).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"372_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","volume":"68","author":"JY Lee","year":"2016","unstructured":"Lee, J. Y. et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol. 68, 184\u2013190 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"372_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.0954-6820.1982.tb01971.x","volume":"211","author":"I Leden","year":"1982","unstructured":"Leden, I. Digoxin-hydroxychloroquine interaction? Acta Med. Scand. 211, 411\u2013412 (1982).","journal-title":"Acta Med. Scand."},{"key":"372_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1046\/j.1365-2125.2000.00197.x","volume":"49","author":"M Somer","year":"2000","unstructured":"Somer, M. et al. Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br. J. Clin. Pharmacol. 49, 549\u2013554 (2000).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"372_CR57","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/ard.2009.126441","volume":"69","author":"TG Kormelink","year":"2010","unstructured":"Kormelink, T. G. et al. Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity. Ann. Rheum. Dis. 69, 2137\u20132144 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR58","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000267861","volume":"27","author":"T Toimela","year":"1995","unstructured":"Toimela, T., Tahti, H. & Salminen, L. Retinal pigment epithelium cell culture as a model for evaluation of the toxicity of tamoxifen and chloroquine. Ophthalmic Res. 27, 150\u2013153 (1995).","journal-title":"Ophthalmic Res."},{"key":"372_CR59","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","volume":"30","author":"B Bannwarth","year":"1996","unstructured":"Bannwarth, B. et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin. Pharmacokinet. 30, 194\u2013210 (1996).","journal-title":"Clin. Pharmacokinet."},{"key":"372_CR60","first-page":"2077","volume":"29","author":"SJ Carmichael","year":"2002","unstructured":"Carmichael, S. J. et al. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 29, 2077\u20132083 (2002).","journal-title":"J. Rheumatol."},{"key":"372_CR61","first-page":"1493","volume":"25","author":"BE van den Borne","year":"1998","unstructured":"van den Borne, B. E. et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J. Rheumatol. 25, 1493\u20131498 (1998).","journal-title":"J. Rheumatol."},{"key":"372_CR62","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0961203308097574","volume":"18","author":"MR Namazi","year":"2009","unstructured":"Namazi, M. R. The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine. Lupus 18, 104\u2013105 (2009).","journal-title":"Lupus"},{"key":"372_CR63","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/art.39194","volume":"67","author":"M Jallouli","year":"2015","unstructured":"Jallouli, M. et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 67, 2176\u20132184 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"372_CR64","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2230.2011.04266.x","volume":"37","author":"N Ezra","year":"2012","unstructured":"Ezra, N. & Jorizzo, J. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus. Clin. Exp. Dermatol. 37, 327\u2013334 (2012).","journal-title":"Clin. Exp. Dermatol."},{"key":"372_CR65","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/acr.22962","volume":"69","author":"J Yeon Lee","year":"2017","unstructured":"Yeon Lee, J. et al. Factors related to blood hydroxychloroquine concentration in patients with systemic lupus erythematosus. Arthritis Care Res. 69, 536\u2013542 (2017).","journal-title":"Arthritis Care Res."},{"key":"372_CR66","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2165\/00002018-200124140-00004","volume":"24","author":"MB Borden","year":"2001","unstructured":"Borden, M. B. & Parke, A. L. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 24, 1055\u20131063 (2001).","journal-title":"Drug Saf."},{"key":"372_CR67","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.autrev.2004.11.009","volume":"4","author":"N Costedoat-Chalumeau","year":"2005","unstructured":"Costedoat-Chalumeau, N. et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun. Rev. 4, 111\u2013115 (2005).","journal-title":"Autoimmun. Rev."},{"key":"372_CR68","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/rheumatology\/kex374","volume":"57","author":"YKO Teng","year":"2017","unstructured":"Teng, Y. K. O. et al. An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology 57, 1707\u20131720 (2017).","journal-title":"Rheumatology"},{"key":"372_CR69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli, L. et al. EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann. Rheum. Dis. 76, 476\u2013485 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR70","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"C Gotestam Skorpen","year":"2016","unstructured":"Gotestam Skorpen, C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann. Rheum. Dis. 75, 795\u2013810 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR71","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","volume":"126","author":"PM Izmirly","year":"2012","unstructured":"Izmirly, P. M. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 126, 76\u201382 (2012).","journal-title":"Circulation"},{"key":"372_CR72","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CRD.0000000000000026","volume":"22","author":"A Saxena","year":"2014","unstructured":"Saxena, A. et al. Prevention and treatment in utero of autoimmune-associated congenital heart block. Cardiol. Rev. 22, 263\u2013267 (2014).","journal-title":"Cardiol. Rev."},{"key":"372_CR73","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/annrheumdis-2016-210927","volume":"76","author":"AR Lisney","year":"2017","unstructured":"Lisney, A. R. et al. High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. Ann. Rheum. Dis. 76, 1476\u20131480 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR74","first-page":"857","volume":"35","author":"D Friedman","year":"2017","unstructured":"Friedman, D. et al. No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine. Clin. Exp. Rheumatol. 35, 857\u2013859 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"372_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/BOR.0000000000000055","volume":"26","author":"LR Sammaritano","year":"2014","unstructured":"Sammaritano, L. R. & Bermas, B. L. Rheumatoid arthritis medications and lactation. Curr. Opin. Rheumatol. 26, 354\u2013360 (2014).","journal-title":"Curr. Opin. Rheumatol."},{"key":"372_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184922","volume":"12","author":"M Circu","year":"2017","unstructured":"Circu, M. et al. Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One 12, e0184922 (2017).","journal-title":"PLoS One"},{"key":"372_CR77","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","volume":"14","author":"M Mauthe","year":"2018","unstructured":"Mauthe, M. et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy 14, 1435\u20131455 (2018).","journal-title":"Autophagy"},{"key":"372_CR78","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ijcard.2012.03.112","volume":"157","author":"A Frustaci","year":"2012","unstructured":"Frustaci, A. et al. Inhibition of cardiomyocyte lysosomal activity in hydroxychloroquine cardiomyopathy. Int. J. Cardiol. 157, 117\u2013119 (2012).","journal-title":"Int. J. Cardiol."},{"key":"372_CR79","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1034\/j.1600-0463.2002.100606.x","volume":"110","author":"SP Sundelin","year":"2002","unstructured":"Sundelin, S. P. & Terman, A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS 110, 481\u2013489 (2002).","journal-title":"APMIS"},{"key":"372_CR80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41580-019-0185-4","volume":"21","author":"A Ballabio","year":"2019","unstructured":"Ballabio, A. & Bonifacino J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101\u2013118 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"372_CR81","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/348600a0","volume":"348","author":"V Lotteau","year":"1990","unstructured":"Lotteau, V. et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature 348, 600\u2013605 (1990).","journal-title":"Nature"},{"key":"372_CR82","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/cmi.2018.2","volume":"15","author":"G Ghislat","year":"2018","unstructured":"Ghislat, G. & Lawrence, T. Autophagy in dendritic cells. Cell Mol. Immunol. 15, 944\u2013952 (2018).","journal-title":"Cell Mol. Immunol."},{"key":"372_CR83","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.it.2016.08.017","volume":"37","author":"C Munz","year":"2016","unstructured":"Munz, C. Autophagy beyond intracellular MHC class II antigen presentation. Trends Immunol. 37, 755\u2013763 (2016).","journal-title":"Trends Immunol."},{"key":"372_CR84","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1084\/jem.20110640","volume":"208","author":"JM Ireland","year":"2011","unstructured":"Ireland, J. M. & Unanue, E. R. Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells. J. Exp. Med. 208, 2625\u20132632 (2011).","journal-title":"J. Exp. Med."},{"key":"372_CR85","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1073\/pnas.75.7.3327","volume":"75","author":"S Ohkuma","year":"1978","unstructured":"Ohkuma, S. & Poole, B. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc. Natl Acad. Sci. USA 75, 3327\u20133331 (1978).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"372_CR86","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2159-8290.CD-18-0706","volume":"9","author":"VW Rebecca","year":"2019","unstructured":"Rebecca, V. W. et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov. 9, 220\u2013229 (2019).","journal-title":"Cancer Discov."},{"key":"372_CR87","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/1756-185X.13063","volume":"20","author":"C Ma","year":"2017","unstructured":"Ma, C. et al. Identifying key genes in rheumatoid arthritis by weighted gene co-expression network analysis. Int. J. Rheum. Dis. 20, 971\u2013979 (2017).","journal-title":"Int. J. Rheum. Dis."},{"key":"372_CR88","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nature07405","volume":"456","author":"SE Ewald","year":"2008","unstructured":"Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658\u2013662 (2008).","journal-title":"Nature"},{"key":"372_CR89","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","volume":"186","author":"A Kuznik","year":"2011","unstructured":"Kuznik, A. et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186, 4794\u20134804 (2011).","journal-title":"J. Immunol."},{"key":"372_CR90","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.1093\/emboj\/17.21.6230","volume":"17","author":"H Hacker","year":"1998","unstructured":"Hacker, H. et al. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 17, 6230\u20136240 (1998).","journal-title":"EMBO J."},{"key":"372_CR91","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1084\/jem.20050630","volume":"202","author":"CM Lau","year":"2005","unstructured":"Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor\/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171\u20131177 (2005).","journal-title":"J. Exp. Med."},{"key":"372_CR92","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1084\/jem.20051696","volume":"202","author":"J Vollmer","year":"2005","unstructured":"Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575\u20131585 (2005).","journal-title":"J. Exp. Med."},{"key":"372_CR93","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1146\/annurev-med-043015-123453","volume":"68","author":"J An","year":"2017","unstructured":"An, J. et al. Antimalarial drugs as immune modulators: new mechanisms for old drugs. Annu. Rev. Med. 68, 317\u2013330 (2017).","journal-title":"Annu. Rev. Med."},{"key":"372_CR94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.celrep.2014.01.003","volume":"6","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell Rep. 6, 421\u2013430 (2014).","journal-title":"Cell Rep."},{"key":"372_CR95","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.molcel.2013.05.022","volume":"51","author":"X Zhang","year":"2013","unstructured":"Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol. Cell 51, 226\u2013235 (2013).","journal-title":"Mol. Cell"},{"key":"372_CR96","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.cytogfr.2014.06.006","volume":"25","author":"C Shu","year":"2014","unstructured":"Shu, C., Li, X. & Li, P. The mechanism of double-stranded DNA sensing through the cGAS-STING pathway. Cytokine Growth Factor Rev. 25, 641\u2013648 (2014).","journal-title":"Cytokine Growth Factor Rev."},{"key":"372_CR97","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.4049\/jimmunol.1402793","volume":"194","author":"J An","year":"2015","unstructured":"An, J. et al. Cutting edge: antimalarial drugs inhibit IFN-\u03b2 production through blockade of cyclic GMP-AMP synthase-DNA interaction. J. Immunol. 194, 4089\u20134093 (2015).","journal-title":"J. Immunol."},{"key":"372_CR98","first-page":"55","volume":"24","author":"BE van den Borne","year":"1997","unstructured":"van den Borne, B. E. et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J. Rheumatol. 24, 55\u201360 (1997).","journal-title":"J. Rheumatol."},{"key":"372_CR99","first-page":"375","volume":"21","author":"DJ Wallace","year":"1994","unstructured":"Wallace, D. J. et al. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J. Rheumatol. 21, 375\u2013376 (1994).","journal-title":"J. Rheumatol."},{"key":"372_CR100","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1177\/0961203393002001041","volume":"2","author":"DJ Wallace","year":"1993","unstructured":"Wallace, D. J. et al. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 2, S13\u2013S15 (1993).","journal-title":"Lupus"},{"key":"372_CR101","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13075-018-1702-0","volume":"20","author":"K Hjorton","year":"2018","unstructured":"Hjorton, K. et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res. Ther. 20, 238 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"372_CR102","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1177\/0961203312437270","volume":"21","author":"R Willis","year":"2012","unstructured":"Willis, R. et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 21, 830\u2013835 (2012).","journal-title":"Lupus"},{"key":"372_CR103","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/03009747309097086","volume":"2","author":"HF Klinefelter","year":"1973","unstructured":"Klinefelter, H. F. & Achurra, A. Effect of gold salts and antimalarials on the rheumatoid factor in rheumatoid arthritis. Scand. J. Rheumatol. 2, 177\u2013182 (1973).","journal-title":"Scand. J. Rheumatol."},{"key":"372_CR104","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/ard.40.5.480","volume":"40","author":"JS Dixon","year":"1981","unstructured":"Dixon, J. S. et al. Biochemical indices of response to hydroxychloroquine and sodium aurothiomalate in rheumatoid arthritis. Ann. Rheum. Dis. 40, 480\u2013488 (1981).","journal-title":"Ann. Rheum. Dis."},{"key":"372_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-017-1393-y","volume":"19","author":"SF Wu","year":"2017","unstructured":"Wu, S. F. et al. Hydroxychloroquine inhibits CD154 expression in CD4(+) T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signaling. Arthritis Res. Ther. 19, 183 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"372_CR106","doi-asserted-by":"publisher","first-page":"348726","DOI":"10.1155\/2014\/348726","volume":"2014","author":"NA Qushmaq","year":"2014","unstructured":"Qushmaq, N. A. & Al-Emadi, S. A. Review on effectiveness of primary prophylaxis in aPLs with and without risk factors for thrombosis: efficacy and safety. ISRN Rheumatol. 2014, 348726 (2014).","journal-title":"ISRN Rheumatol."},{"key":"372_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","volume":"65","author":"E Nuri","year":"2017","unstructured":"Nuri, E. et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol. Res. 65, 17\u201324 (2017).","journal-title":"Immunol. Res."},{"key":"372_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","volume":"80","author":"S Dadoun","year":"2013","unstructured":"Dadoun, S. et al. Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. Joint Bone Spine 80, 29\u201333 (2013).","journal-title":"Joint Bone Spine"},{"key":"372_CR109","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","volume":"37","author":"J van den Hoek","year":"2017","unstructured":"van den Hoek, J. et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol. Int. 37, 487\u2013493 (2017).","journal-title":"Rheumatol. Int."},{"key":"372_CR110","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/acr.23018","volume":"69","author":"JA Avina-Zubieta","year":"2017","unstructured":"Avina-Zubieta, J. A. et al. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res. 69, 849\u2013856. (2017).","journal-title":"Arthritis Care Res."},{"key":"372_CR111","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3899\/jrheum.161121","volume":"44","author":"K Tselios","year":"2017","unstructured":"Tselios, K., Gladman, D. D., Su, J., Ace, O. & Urowitz, M. B. Evolution of risk factors for atherosclerotic cardiovascular events in systemic lupus erythematosus: a longterm prospective study. J. Rheumatol. 44 1841\u20131849 (2017).","journal-title":"J. Rheumatol."},{"key":"372_CR112","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/rheumatology\/kep225","volume":"49","author":"IT Padol","year":"2010","unstructured":"Padol, I. T. & Hunt, R. H. Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation. Rheumatology 49, 837\u2013843 (2010).","journal-title":"Rheumatology"},{"key":"372_CR113","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/2042018814547204","volume":"5","author":"MP Hage","year":"2014","unstructured":"Hage, M. P., Al-Badri, M. R. & Azar, S. T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. Ther. Adv. Endocrinol. Metab. 5, 77\u201385 (2014).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"372_CR114","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/rheumatology\/kem378","volume":"47","author":"DU Cansu","year":"2008","unstructured":"Cansu, D. U. & Korkmaz, C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology 47, 378\u2013379 (2008).","journal-title":"Rheumatology"},{"key":"372_CR115","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.161351","volume":"44","author":"S Fasano","year":"2017","unstructured":"Fasano, S. et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J. Rheumatol. 44, 1032\u20131038 (2017).","journal-title":"J. Rheumatol."},{"key":"372_CR116","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ebiom.2016.10.034","volume":"14","author":"CG Towers","year":"2016","unstructured":"Towers, C. G. & Thorburn, A. Therapeutic targeting of autophagy. EBioMedicine 14, 15\u201323 (2016).","journal-title":"EBioMedicine"},{"key":"372_CR117","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","volume":"112","author":"JH Rand","year":"2008","unstructured":"Rand, J. H. et al. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-\u03b22-glycoprotein I complexes to phospholipid bilayers. Blood 112, 1687\u20131695 (2008).","journal-title":"Blood"},{"key":"372_CR118","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0049-3848(94)90270-4","volume":"74","author":"V Jancinova","year":"1994","unstructured":"Jancinova, V., Nosal, R. & Petrikova, M. On the inhibitory effect of chloroquine on blood platelet aggregation. Thromb. Res. 74, 495\u2013504 (1994).","journal-title":"Thromb. Res."},{"key":"372_CR119","first-page":"143","volume":"50","author":"E Bertrand","year":"1990","unstructured":"Bertrand, E. et al. Antiaggregation action of chloroquine. Med. Trop. 50, 143\u2013146 (1990).","journal-title":"Med. Trop."},{"key":"372_CR120","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/0049-3848(95)00028-3","volume":"77","author":"R Nosal","year":"1995","unstructured":"Nosal, R., Jancinova, V. & Petrikova, M. Chloroquine inhibits stimulated platelets at the arachidonic acid pathway. Thromb. Res. 77, 531\u2013542 (1995).","journal-title":"Thromb. Res."},{"key":"372_CR121","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212614","volume":"14","author":"S Miranda","year":"2019","unstructured":"Miranda, S. et al. Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: role of reduced inflammation and endothelial dysfunction. PLoS One 14, e0212614 (2019).","journal-title":"PLoS One"},{"key":"372_CR122","doi-asserted-by":"publisher","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","volume":"96","author":"MH Edwards","year":"1997","unstructured":"Edwards, M. H. et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 96, 4380\u20134384 (1997).","journal-title":"Circulation"},{"key":"372_CR123","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","volume":"45","author":"MN Lazarus","year":"2006","unstructured":"Lazarus, M. N. et al. Incidence of cancer in a cohort of patients with primary Sjogren\u2019s syndrome. Rheumatology 45, 1012\u20131015 (2006).","journal-title":"Rheumatology"},{"key":"372_CR124","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3899\/jrheum.161063","volume":"44","author":"A Srinivasa","year":"2017","unstructured":"Srinivasa, A., Tosounidou, S. & Gordon, C. Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue? J. Rheumatol. 44, 398 (2017).","journal-title":"J. Rheumatol."},{"key":"372_CR125","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1002\/mus.21091","volume":"38","author":"H Abdel-Hamid","year":"2008","unstructured":"Abdel-Hamid, H., Oddis, C. V. & Lacomis, D. Severe hydroxychloroquine myopathy. Muscle Nerve 38, 1206\u20131210 (2008).","journal-title":"Muscle Nerve"},{"key":"372_CR126","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s10067-017-3579-8","volume":"36","author":"K Jafri","year":"2017","unstructured":"Jafri, K. et al. Antimalarial myopathy in a systemic lupus erythematosus patient with quadriparesis and seizures: a case-based review. Clin. Rheumatol. 36, 1437\u20131444 (2017).","journal-title":"Clin. Rheumatol."},{"key":"372_CR127","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/neup.12520","volume":"38","author":"S Khosa","year":"2018","unstructured":"Khosa, S. et al. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. Neuropathology 38, 646\u2013652 (2018).","journal-title":"Neuropathology"},{"key":"372_CR128","first-page":"2927","volume":"27","author":"M Stein","year":"2000","unstructured":"Stein, M., Bell, M. J. & Ang, L. C. Hydroxychloroquine neuromyotoxicity. J. Rheumatol. 27, 2927\u20132931 (2000).","journal-title":"J. Rheumatol."},{"key":"372_CR129","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/postgradmedj-2017-135236","volume":"94","author":"MU Dogar","year":"2018","unstructured":"Dogar, M. U. et al. Hydroxychloroquine-induced restrictive cardiomyopathy: a case report. Postgrad. Med. J. 94, 185\u2013186 (2018).","journal-title":"Postgrad. Med. J."},{"key":"372_CR130","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.007059","volume":"11","author":"ICY Chang","year":"2018","unstructured":"Chang, I. C. Y. et al. Hydroxychloroquine-mediated cardiotoxicity with a false-positive 99mTechnetium-labeled pyrophosphate scan for transthyretin-related cardiac amyloidosis. Circ. Cardiovasc. Imaging 11, e007059 (2018).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"372_CR131","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre, C. et al. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 41, 919\u2013931 (2018).","journal-title":"Drug Saf."},{"key":"372_CR132","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/rheumatology\/kel402","volume":"46","author":"N Costedoat-Chalumeau","year":"2007","unstructured":"Costedoat-Chalumeau, N. et al. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology 46, 808\u2013810 (2007).","journal-title":"Rheumatology"},{"key":"372_CR133","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","volume":"14","author":"A Jorge","year":"2018","unstructured":"Jorge, A. et al. Hydroxychloroquine retinopathy \u2013 implications of research advances for rheumatology care. Nat. Rev. Rheumatol. 14, 693\u2013703 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"372_CR134","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","volume":"123","author":"MF Marmor","year":"2016","unstructured":"Marmor, M. F. et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology 123, 1386\u20131394 (2016).","journal-title":"Ophthalmology"},{"key":"372_CR135","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41433-018-0136-x","volume":"32","author":"IH Yusuf","year":"2018","unstructured":"Yusuf, I. H. et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32, 1168\u20131173 (2018).","journal-title":"Eye"},{"key":"372_CR136","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/jps.2600820610","volume":"82","author":"AC MacIntyre","year":"1993","unstructured":"MacIntyre, A. C. & Cutler, D. J. Kinetics of chloroquine uptake into isolated rat hepatocytes. J. Pharm. Sci. 82, 592\u2013600 (1993).","journal-title":"J. Pharm. Sci."},{"key":"372_CR137","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1002\/art.22156","volume":"54","author":"N Costedoat-Chalumeau","year":"2006","unstructured":"Costedoat-Chalumeau, N. et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 3284\u20133290 (2006).","journal-title":"Arthritis Rheum."},{"key":"372_CR138","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/cpt.885","volume":"103","author":"N Costedoat-Chalumeau","year":"2018","unstructured":"Costedoat-Chalumeau, N. et al. A prospective international study on adherence to treatment in 305 patients with flaring SLE: assessment by drug levels and self-administered questionnaires. Clin. Pharmacol. Ther. 103, 1074\u20131082 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"372_CR139","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1136\/jim-2016-000065","volume":"64","author":"M Bethel","year":"2016","unstructured":"Bethel, M. et al. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. J. Investig. Med. 64, 908\u2013910 (2016).","journal-title":"J. Investig. Med."},{"key":"372_CR140","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.kint.2018.02.003","volume":"94","author":"CJ Sperati","year":"2018","unstructured":"Sperati, C. J. & Rosenberg, A. Z. Hydroxychloroquine-induced mimic of renal Fabry disease. Kidney Int. 94, 634 (2018).","journal-title":"Kidney Int."},{"key":"372_CR141","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/bjd.16782","volume":"179","author":"IH Yusuf","year":"2018","unstructured":"Yusuf, I. H., Lotery, A. J. & Ardern-Jones, M. R. Joint recommendations for retinal screening in long-term users of hydroxychloroquine and chloroquine in the United Kingdom, 2018. Br. J. Dermatol. 179, 995\u2013996 (2018).","journal-title":"Br. J. Dermatol."},{"key":"372_CR142","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1001\/jamaophthalmol.2014.3459","volume":"132","author":"RB Melles","year":"2014","unstructured":"Melles, R. B. & Marmor, M. F. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 132, 1453\u20131460 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"372_CR143","doi-asserted-by":"publisher","unstructured":"Costedoat-Chalumeau, N., Isenberg, D. & Petri, M. Letter in response to the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215573 (2019).","DOI":"10.1136\/annrheumdis-2019-215573"},{"key":"372_CR144","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","volume":"5","author":"TB Karasic","year":"2019","unstructured":"Karasic, T. B. et al. Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial. JAMA Oncol. 5, 993\u2013998 (2019).","journal-title":"JAMA Oncol."},{"key":"372_CR145","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.4161\/auto.28984","volume":"10","author":"MR Rosenfeld","year":"2014","unstructured":"Rosenfeld, M. R. et al. A phase I\/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10, 1359\u20131368 (2014).","journal-title":"Autophagy"},{"key":"372_CR146","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4161\/auto.29118","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala, R. et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 10, 1369\u20131379 (2014).","journal-title":"Autophagy"},{"key":"372_CR147","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/auto.29119","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala, R. et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 10, 1391\u20131402 (2014).","journal-title":"Autophagy"},{"key":"372_CR148","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/IAE.0000000000002027","volume":"39","author":"AA Nti","year":"2019","unstructured":"Nti, A. A. et al. Frequent subclinical macular changes in combined BRAF\/MEK inhibition with high-dose hydroxychloroquine as treatment for advanced metastatic braf mutant melanoma: preliminary results from a phase I\/II clinical treatment trial. Retina 39, 502\u2013513 (2019).","journal-title":"Retina"},{"key":"372_CR149","first-page":"3","volume":"77","author":"T Dorner","year":"2006","unstructured":"Dorner, T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J. Rheumatol. Suppl. 77, 3\u201311 (2006).","journal-title":"J. Rheumatol. Suppl."},{"key":"372_CR150","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cbf.3385","volume":"37","author":"N Liang","year":"2019","unstructured":"Liang, N. et al. Multifaceted roles of ATM in autophagy: from nonselective autophagy to selective autophagy. Cell Biochem. Funct. 37, 177\u2013184 (2019).","journal-title":"Cell Biochem. Funct."},{"key":"372_CR151","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cellsig.2015.02.025","volume":"27","author":"MS Bahia","year":"2015","unstructured":"Bahia, M. S. et al. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory- and immune-related disorders. Cell Signal. 27, 1039\u20131055 (2015).","journal-title":"Cell Signal."},{"key":"372_CR152","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.compbiolchem.2019.02.005","volume":"79","author":"MA Khanfar","year":"2019","unstructured":"Khanfar, M. A. & Alqtaishat, S. Discovery of potent IRAK-4 inhibitors as potential anti-inflammatory and anticancer agents using structure-based exploration of IRAK-4 pharmacophoric space coupled with QSAR analyses. Comput. Biol. Chem. 79, 147\u2013154 (2019).","journal-title":"Comput. Biol. Chem."},{"key":"372_CR153","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.actbio.2018.10.027","volume":"82","author":"S Kanvinde","year":"2018","unstructured":"Kanvinde, S. et al. Pharmacokinetics and efficacy of orally administered polymeric chloroquine as macromolecular drug in the treatment of inflammatory bowel disease. Acta Biomater. 82, 158\u2013170 (2018).","journal-title":"Acta Biomater."},{"key":"372_CR154","unstructured":"Messai, A. in Emerging Research on Bioinspired Materials Engineering (ed. Bououdina, M.) 160\u2013196 (IGI Global, 2016)."},{"key":"372_CR155","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs Accessdata.fda.gov https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=006002 (2014)."},{"key":"372_CR156","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs Accessdata.fda.gov https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=009768 (2014)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0372-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0372-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-020-0372-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:21:28Z","timestamp":1684606888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-020-0372-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["372"],"URL":"https:\/\/doi.org\/10.1038\/s41584-020-0372-x","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"9 January 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}